Date published: 2026-5-18

1-800-457-3801

SCBT Portrait Logo
Seach Input

20S Proteasome α1 Inhibitors

20S Proteasome α1 inhibitors comprise a specific class of chemical compounds that modulate the activity of the α1 subunit within the 20S proteasome complex. The 20S proteasome is a fundamental cellular machinery responsible for degrading and recycling intracellular proteins, thereby influencing a myriad of cellular processes. The α1 subunit is a crucial component of the 20S proteasome's catalytic core, contributing to its ability to cleave targeted proteins into smaller peptides. These inhibitors function by binding to the α1 subunit, inducing intricate modifications in its catalytic activity. The primary role of the α1 subunit involves the cleavage of proteins at specific sites during the proteolysis process. 20S Proteasome α1 inhibitors are meticulously designed to interact with precise binding sites on the subunit, disrupting its natural interactions with substrate proteins and other catalytic subunits. This interaction perturbs the α1 subunit's capability to cleave proteins effectively, leading to downstream consequences on protein turnover and cellular processes that rely on proteasomal degradation.

The development of these inhibitors is a sophisticated endeavor that involves structural analysis, computational modeling, and chemical synthesis to engineer compounds with the appropriate properties to achieve the desired impact on the α1 subunit's activity. As research into 20S Proteasome α1 inhibitors advances, scientists strive to unravel the intricate mechanisms governing the interaction between these inhibitors and the α1 subunit. A comprehensive understanding of these mechanisms holds the promise of shedding light on the broader landscape of protein homeostasis and cellular regulation, revealing new insights into the intricacies of protein degradation orchestrated by the 20S proteasome. By delving into the complexities of α1 subunit inhibition, researchers aim to deepen our understanding of the cellular processes influenced by proteasomal activity and gain novel perspectives in the realm of protein turnover.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Carfilzomib

868540-17-4sc-396755
5 mg
$41.00
(0)

Carfilzomib is a proteasome inhibitor investigated for multiple myeloma. It targets multiple proteasome subunits, including the α1 subunit.

Ixazomib

1072833-77-2sc-489103
sc-489103A
10 mg
50 mg
$311.00
$719.00
(0)

Ixazomib is another proteasome inhibitor investigated for multiple myeloma. It inhibits the chymotrypsin-like activity of the proteasome, affecting multiple subunits.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Bortezomib was the first proteasome inhibitor investigated for multiple myeloma. It also targets the chymotrypsin-like activity of the proteasome, affecting the α1 subunit.